Surprise ODAC vote against recommendation for approval of Panobinostat, 5-2.

On November 6, 2014 an FDA advisory panel, the Oncologic Drugs Advisory Committee (ODAC), held a hearing on panobinostat, a drug in development to treat relapsed myeloma. The committee voted not to recommend panobinostat for FDA approval. IMF staff members and myeloma patients testified on behalf of panobinostat, sharing the critical need for an array of treatment options for myeloma patients.
Source: International Myeloma Foundation - Category: Hematology Source Type: news